JIB-04 100mg
100mg
| Purity Not Available
Adooq Bioscience
JIB-04 is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
More Information
Supplier Page
UNC569 50mg
50mg
| Purity Not Available
Adooq Bioscience
UNC569 is a novel small-molecule MER inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. UNC569 is the first small-molecule Mer inhibitor. UNC569 inhibited Mer activation and downstream signaling through ERK1/2 and AKT.
More Information
Supplier Page
UNC569 25mg
25mg
| Purity Not Available
Adooq Bioscience
UNC569 is a novel small-molecule MER inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. UNC569 is the first small-molecule Mer inhibitor. UNC569 inhibited Mer activation and downstream signaling through ERK1/2 and AKT.
More Information
Supplier Page
UNC569 10mg
10mg
| Purity Not Available
Adooq Bioscience
UNC569 is a novel small-molecule MER inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. UNC569 is the first small-molecule Mer inhibitor. UNC569 inhibited Mer activation and downstream signaling through ERK1/2 and AKT.
More Information
Supplier Page
JIB-04 50mg
50mg
| Purity Not Available
Adooq Bioscience
JIB-04 is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
More Information
Supplier Page
Adooq Bioscience
BMS303141 is a potent inhibitor of ATP citrate lyase (ACL). BMS303141 inhibits lipid synthesis in HepG2 cells with an IC50 of 8 ??M, and lowers plasma triglycerides in a murine hyperlipdemia model.
More Information
Supplier Page
Adooq Bioscience